Last reviewed · How we verify

HEXAMINOLEVULINATE — Competitive Intelligence Brief

HEXAMINOLEVULINATE (HEXAMINOLEVULINATE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed Small molecule Live · refreshed every 30 min

Target snapshot

HEXAMINOLEVULINATE (HEXAMINOLEVULINATE). Cysview is converted into PpIX and PAPs, which accumulate in neoplastic cells and fluoresce under specific light, aiding cystoscopic detection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HEXAMINOLEVULINATE TARGET HEXAMINOLEVULINATE marketed 2010-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HEXAMINOLEVULINATE — Competitive Intelligence Brief. https://druglandscape.com/ci/hexaminolevulinate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing